EXECUTIVE INTERVIEW – Ezose Sciences: High-Throughput Glycomics for Biomarker Discovery – Bringing Glycan Analysis Into Everyday Research
Scott Siegel, PhD, VP of Business Development at Ezose, discusses how his unique company is catalyzing progress across an emerging research front.
Jos Raats, PhD, says ModiQuest has undertaken a number of studies into specific anti-Citrulline antibodies and has discovered a subset (family) of rCit-hMabs, which could provide a valuable therapeutic in the treatment of early onset RA.
Carl Levoguer, PhD, examines how laser diffraction technology has been fashioned to powerfully support every stage of the drug development cycle.
Robert Gwozdz, MPharm, presents an overview of polymers used in the more exotic and technically challenging dosage forms involving MR as well as those used for enhancing the dissolution and bioavailability of poorly soluble APIs.
Mr. Ben Moga, President of Ratio, Inc., talks about his company’s focus on self-injection in a homecare setting and how Ratio is pitting the patch injector against conventional autoinjectors in what is projected to be a $15.8 billion injectable drug delivery device market.
Contributor Cindy H. Dubin posed a series of questions to several CDMOs to find out how they are positioned to help Pharma navigate the waters of patent expirations, rising costs, shrinking timelines, and budget constraints.
DRUG DEVELOPMENT – Design & Development of Atorvastatin Orally Disintegrating Tablets & Their Evaluation by Electronic Tongue
Rakesh Kumar Bhasin, MPharm, and Pradip Kumar Ghosh, PhD, design and develop a good taste-masked atorvastatin ODT that matched the in vitro release profile of Lipitor.
FORMULATION DEVELOPMENT – In Vitro Diffusion Studies in Transdermal Research: A Synthetic Membrane Model in Place of Human Skin
Vivek Joshi, PhD, David Brewster, and Peter Colonero present data on the applicability of a synthetic membrane (Strat-MTM) for in vitro transdermal diffusion studies in place of human or animal skin as a model.
Suniket Fulzele, PhD; Derek Moe, PhD; and Ehab Hamed, PhD; review the lyophilized wafer technology, specifically Lyoc, that offered the world’s first ODT, ODA Lyoc (sodium saccharinate and flamenol) in 1968.
THERAPEUTIC FOCUS – Therapeutic Advances in Non-Small Cell Lung Cancer: Targeting Activating & Resistant Forms of EGFR & ALK
William C. Shakespeare, PhD, provides a brief review of both targets, including approved agents, mechanisms of resistance, and next-generation agents in development; many designed specifically to target disease-resistant mutations.
EXCLUSIVE ONLINE CONTENT
AC Immune SA recently announced a research partnership with leading scientists in the Perelman School of Medicine at the University of Pennsylvania (Penn) focused on studying the pathological mechanisms of…..
CureVac AG recently announced it has entered into a Collaborative Research Agreement with Yale University for discovery research into mRNA-based……
Saama Technologies, Inc. recently announced it has signed a definitive agreement to acquire Comprehend Systems, Inc. to create an exciting, enhanced suite of………..
Developing ODTs is a worldwide trend. In recent years, new excipients and excipient blends have enabled manufacturers to produce ODTs using conventional equipment, ie, blenders and tablet presses. One such product is GRANFILLER-D………
MilliporeSigma has acquired BSSN Software, a Darmstadt, Germany-based laboratory informatics company that makes data more readily accessible for ease of integration, collaboration, analysis and…..